We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

378 hedge funds and large institutions have $8.35B invested in Royalty Pharma in 2024 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 141 increasing their positions, 127 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

222% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $4.19M

11% more repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 127

1.94% more ownership

Funds ownership: 68.15% → 70.09% (+1.9%)

7% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 56

0% more funds holding

Funds holding: 378 → 378 (0)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

10% less capital invested

Capital invested by funds: $9.24B → $8.35B (-$885M)

Holders
378
Holders Change
–
Holders Change %
0%
% of All Funds
5.46%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
60
Increased
141
Reduced
127
Closed
56
Calls
$13.5M
Puts
$4.19M
Net Calls
+$9.31M
Net Calls Change
+$4.69M

Top Buyers

1
Swedbank
Swedbank
Sweden
+$300M
2
BlackRock
BlackRock
New York
+$50.2M
3
BGIM
Brandywine Global Investment Management
Pennsylvania
+$45.4M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$29.5M
5
Invesco
Invesco
Georgia
+$29.5M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$159M
2
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$81.4M
3
Millennium Management
Millennium Management
New York
-$64.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$15.8M
5
CSS
Cubist Systematic Strategies
Connecticut
-$14.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
HIA
376
Harbor Investment Advisory
Maryland
$105 +$111 +4 New
LFG
377
Larson Financial Group
Missouri
$53 – – –
TFM
378
TFC Financial Management
Massachusetts
$27 -$776 -28 -97%
DJSG
379
D.J. St. Germain
Massachusetts
$6 – – –
Point72 Asset Management
380
Point72 Asset Management
Connecticut
– -$15.8M -521,200 Closed
CSS
381
Cubist Systematic Strategies
Connecticut
– -$14.5M -477,047 Closed
GIM
382
Generate Investment Management
New Zealand
– -$12M -396,342 Closed
PCM
383
Portolan Capital Management
Massachusetts
– -$8.76M -288,378 Closed
JGC
384
J. Goldman & Co
New York
– -$8.06M -265,334 Closed
JFG
385
Jefferies Financial Group
New York
– -$4.16M -137,000 Closed
HF
386
HRT Financial
New York
– -$3.95M -130,188 Closed
MWP
387
MYCIO Wealth Partners
Pennsylvania
– -$3.45M -113,652 Closed
Citadel Advisors
388
Citadel Advisors
Florida
– -$2.71M -97,919 Closed
Caisse de Depot et Placement du Quebec (CDPQ)
389
Caisse de Depot et Placement du Quebec (CDPQ)
Quebec, Canada
– -$2.81M -92,452 Closed
Nisa Investment Advisors
390
Nisa Investment Advisors
Missouri
– -$2.28M -75,000 Closed
CIC
391
Cornercap Investment Counsel
Georgia
– -$2.04M -67,314 Closed
PD
392
Point72 (DIFC)
United Arab Emirates
– -$1.99M -65,582 Closed
TC
393
Taika Capital
Florida
– -$1.33M -43,740 Closed
Wealthfront Advisers
394
Wealthfront Advisers
California
– -$1.03M -33,821 Closed
LTAS
395
Linden Thomas Advisory Services
North Carolina
– -$1.02M -33,674 Closed
FDP
396
Financiere des Professionnels
Quebec, Canada
– -$1M -32,931 Closed
SWS
397
SYSTM Wealth Solutions
Illinois
– -$997K -32,836 Closed
ARG
398
Advisory Resource Group
Oklahoma
– -$824K -27,121 Closed
PHK
399
Point72 Hong Kong
Hong Kong
– -$814K -26,789 Closed
PCM
400
Prelude Capital Management
New York
– -$694K -22,866 Closed
14 15
16
17 18

RPRX Hedge Fund Activity: Q2 2024 in Review

378 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2024, worth a combined $8.35B — down 9.6% from $9.24B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new RPRX positions and 56 closed out — a net gain of 4 holders — while 141 added to existing stakes and 127 trimmed.

The largest buyer was Swedbank, opening a new position worth an estimated $300M. The largest seller was Fidelity Investments, cutting an estimated $159M.

  • 378 institutional investors held Royalty Pharma (RPRX) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $8.35B of Royalty Pharma stock for Q2 2024, down 9.6% quarter-over-quarter.
  • 60 funds opened new Royalty Pharma positions in Q2 2024 and 56 closed out, a net change of +4 holders.
  • The largest Royalty Pharma buyer in Q2 2024 was Swedbank, an estimated $300M added.
  • The largest Royalty Pharma seller in Q2 2024 was Fidelity Investments, an estimated $159M sold.

Based on aggregated 13F filings for Q2 2024.